Innovative Russian drug product mobilizes human immune system to fight cancer

06.02.2017

Innovative Russian drug product mobilizes human immune system to fight cancer

Revolutionary Russian anti-cancer anti-PD1 medicine candidate has successfully ended pre-clinical animal trials, i.e. on primates. So far the product has demonstrated higher efficacy than the only two approved medicines acting  against the same therapeutic target – pembrolizumab from Merck and nivolumab from BMS. 

BIOCAD is now preparing for the first international multi-center clinical trials. Patients in Russia will be among the first to get access to the new generation therapy.  The medicine is expected to be available to patients as early as in 2018 or 2019.

More Category: Media release
Advanced rheumatoid arthritis medicine developed in Russia

11.07.2016

Advanced rheumatoid arthritis medicine developed in Russia

Biotechnological company BIOCAD has developed innovative medicine for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other autoimmune diseases.

More Category: Media release
Patients received no cancer medicines because of unfair competition from Hoffmann-La Roche in Sri Lanka

11.07.2016

Patients received no cancer medicines because of unfair competition from Hoffmann-La Roche in Sri Lanka

Due to unsubstantiated, frivolous claims by Swiss drug-maker F. Hoffmann-La Roche, Ltd. in a desperate attempt to cease the distribution of the Russian-made anti-tumor biosimilar products, as well as seeking to revoke BIOCAD’s product market authorization in Sri Lanka, cancer patients in this South-East country haven’t received the essential anti-cancer drugs trastuzumab and bevacizumab in time. After a series of hearings, in late June the Court of Appeals of Sri Lanka finally dismissed the claims from the Swiss originator and terminated interim in relief

More Category: Media release
BIOCAD announces the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation

11.02.2016

BIOCAD announces the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation

The trastuzumab biosimilar, to be marketed under the trade name HERtiCAD™, is the first trastuzumab biosimilar to receive authorization from the Russian regulatory body

More Category: Media release
Russia’s only project to supply local high-tech anti-cancer drugs abroad  continues with the first shipment to Vietnam

11.02.2016

Russia’s only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam

Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam.

More Category: Media release